Theravance, Inc.

Theravance Biopharma R&d IP, LLC

Ontogen Corporation

Advanced Medicine, Inc.

Edmund J Moran

James Bradley Aggen

Seok-Ki Choi

Daniel Marquess

Paul Ross Fatheree

Martin Sheringham Linsell

Matthew B Nodwell

Adam D Hughes

Melissa Fleury

Roland Gendron

John R Jacobsen

John H Griffin

Erik Fenster

Daniel D Long

Sean Gary Trapp

Michael Robert Leadbetter

Yu-Hua Ji

S Derek Turner

Timothy J Church

Jonathan W Wray

Glenn D Crater

Jason P Chinn

Christopher Noel Barnes

Srikanth Pendyala

Mathai Mammen

Robert Murray McKinnell

David A Oare

J Kevin Judice

John L Pace

Romaine R Maiefski

Adnan M Mjalli

Xiaodong Cao

Thomas James Baiga

Eric Fournier

Yongqui Mu

Burton Christensen

Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEVless than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEVand trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.

Methods for treating chronic obstructive pulmonary disease

In one aspect, the invention relates to compounds having the formula:

Neprilysin inhibitors

In one aspect, the invention relates to compounds having the formula: where R-R, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

This invention provides cephalosporin compounds and salts thereof. Such compounds are useful for preparing cross-linked glycopeptide-cephalosporin antibiotics.

Cephalosporin compounds

The invention provides novel &#x3b2;adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with &#x3b2;adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

[object Object]

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.

Cross-linked glycopeptide-cephalosporin antibiotics

The invention provides novel &#x3b2;adrenergic receptor agonist compounds of formula (I):  wherein R-Rand w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with &#x3b2;adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

The invention provides novel &#x3b2;adrenergic receptor agonist compounds of formula (I): 

Aryl aniline &#x3b2;2 adrenergic receptor agonists

Growing community of inventors

San Francisco, CA, United States of America

Edmund J Moran